{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T04:05:46Z","timestamp":1748664346977,"version":"3.41.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY24H160012"],"award-info":[{"award-number":["LY24H160012"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) dominate the treatment of chronic myeloid leukemia (CML) over the past decades. In this study, we reported an unexpected role of neddylation inhibitors in desensitizing the therapeutic efficacy of BCR::ABL1-targeting TKIs in CML. Unlike their function in reducing drug resistance in many solid tumors, we revealed that neddylation inhibitors counteracted the cytotoxicity of TKIs against CML cells, both in cellular experiments and in animal model. Conversely, neddylation agonist sensitized the function of TKIs. RNA sequencing data revealed that neddylation inhibitor reversed the transcriptomic changes induced by TKI. Co-immunoprecipitation (co-IP) assay identified ABL1 kinase domain as a novel substrate for neddylation. Furthermore, an artificial intelligence (AI) 3-Dimensional spatial structure binding technology was employed to predict the impact of neddylation on the structure of ABL1 kinase domain. Finally, we provided potential evidence showing that TKI therapy decreased the expression of neddylation enzymes in the bone marrow of CML patients. Hence, our study offers new insights into the post-translational modification (PTM)-mediated drug resistance, and highlights the potential clinical benefits of neddylation agonists in improving the responsiveness of BCR::ABL1 TKIs in CML.<\/jats:p>","DOI":"10.1038\/s41598-025-04153-7","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:01:44Z","timestamp":1748584904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neddylation status determines the therapeutic sensitivity of tyrosine kinase inhibitors in chronic myeloid leukemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Congyi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yikai","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuting","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiongyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunkun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuehai","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"4153_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J Groffen","year":"1984","unstructured":"Groffen, J. et al. Philadelphia chromosomal breakpoints are clustered within a limited region, Bcr, on chromosome 22. Cell 36, 93\u201399. https:\/\/doi.org\/10.1016\/0092-8674(84)90077-1 (1984).","journal-title":"Cell"},{"key":"4153_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo, T. G., Pendergast, A. M., Muller, A. J. & Witte, O. N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079\u20131082. https:\/\/doi.org\/10.1126\/science.2408149 (1990).","journal-title":"Science"},{"key":"4153_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun, T. P., Eide, C. A. & Druker, B. J. Response and resistance to BCR-ABL1-Targeted therapies. Cancer Cell. 37, 530\u2013542. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.006 (2020).","journal-title":"Cancer Cell."},{"key":"4153_CR4","doi-asserted-by":"publisher","first-page":"742802","DOI":"10.3389\/fgene.2021.742802","volume":"12","author":"M Amir","year":"2021","unstructured":"Amir, M. & Javed, S. A. Review on the therapeutic role of TKIs in case of CML in combination with epigenetic drugs. Front. Genet. 12, 742802. https:\/\/doi.org\/10.3389\/fgene.2021.742802 (2021).","journal-title":"Front. Genet."},{"key":"4153_CR5","doi-asserted-by":"publisher","unstructured":"Alves, R. et al. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13194820 (2021).","DOI":"10.3390\/cancers13194820"},{"key":"4153_CR6","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.molcel.2021.03.015","volume":"81","author":"EK Keenan","year":"2021","unstructured":"Keenan, E. K., Zachman, D. K. & Hirschey, M. D. Discovering the landscape of protein modifications. Mol. Cell. 81, 1868\u20131878. https:\/\/doi.org\/10.1016\/j.molcel.2021.03.015 (2021).","journal-title":"Mol. Cell."},{"key":"4153_CR7","doi-asserted-by":"publisher","first-page":"1240115","DOI":"10.3389\/fonc.2023.1240115","volume":"13","author":"H Dutta","year":"2023","unstructured":"Dutta, H. & Jain, N. Post-translational modifications and their implications in cancer. Front. Oncol. 13, 1240115. https:\/\/doi.org\/10.3389\/fonc.2023.1240115 (2023).","journal-title":"Front. Oncol."},{"key":"4153_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41392-024-01800-9","volume":"9","author":"S Zhang","year":"2024","unstructured":"Zhang, S., Yu, Q., Li, Z., Zhao, Y. & Sun, Y. Protein neddylation and its role in health and diseases. Signal. Transduct. Target. Ther. 9, 85. https:\/\/doi.org\/10.1038\/s41392-024-01800-9 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"4153_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/978-981-15-1025-0_18","volume":"1217","author":"L Zhou","year":"2020","unstructured":"Zhou, L. & Jia, L. Targeting protein neddylation for Cancer therapy. Adv. Exp. Med. Biol. 1217, 297\u2013315. https:\/\/doi.org\/10.1007\/978-981-15-1025-0_18 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"4153_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jhep.2022.02.007","volume":"77","author":"P Olaizola","year":"2022","unstructured":"Olaizola, P. et al. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. J. Hepatol. 77, 177\u2013190. https:\/\/doi.org\/10.1016\/j.jhep.2022.02.007 (2022).","journal-title":"J. Hepatol."},{"key":"4153_CR11","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/ncb1483","volume":"8","author":"F Gao","year":"2006","unstructured":"Gao, F., Cheng, J., Shi, T. & Yeh, E. T. Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFkappaB-dependent transcription. Nat. Cell. Biol. 8, 1171\u20131177. https:\/\/doi.org\/10.1038\/ncb1483 (2006).","journal-title":"Nat. Cell. Biol."},{"key":"4153_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41422-020-00443-z","volume":"31","author":"P Xie","year":"2021","unstructured":"Xie, P. et al. Neddylation of PTEN regulates its nuclear import and promotes tumor development. Cell. Res. 31, 291\u2013311. https:\/\/doi.org\/10.1038\/s41422-020-00443-z (2021).","journal-title":"Cell. Res."},{"key":"4153_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12943-019-0979-1","volume":"18","author":"L Zhou","year":"2019","unstructured":"Zhou, L., Jiang, Y., Luo, Q., Li, L. & Jia, L. Neddylation: a novel modulator of the tumor microenvironment. Mol. Cancer. 18, 77. https:\/\/doi.org\/10.1186\/s12943-019-0979-1 (2019).","journal-title":"Mol. Cancer"},{"key":"4153_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41420-020-00296-w","volume":"6","author":"J Ferris","year":"2020","unstructured":"Ferris, J. et al. Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer. Cell. Death Discov 6, 61. https:\/\/doi.org\/10.1038\/s41420-020-00296-w (2020).","journal-title":"Cell. Death Discov"},{"key":"4153_CR15","doi-asserted-by":"publisher","first-page":"653882","DOI":"10.3389\/fcell.2021.653882","volume":"9","author":"W Gai","year":"2021","unstructured":"Gai, W., Peng, Z., Liu, C. H., Zhang, L. & Jiang, H. Advances in Cancer treatment by targeting the neddylation pathway. Front. Cell. Dev. Biol. 9, 653882. https:\/\/doi.org\/10.3389\/fcell.2021.653882 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"4153_CR16","doi-asserted-by":"publisher","unstructured":"Li, Y. et al. SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47\/SIRPalpha axis. J. Clin. Invest. 133 https:\/\/doi.org\/10.1172\/JCI162870 (2023).","DOI":"10.1172\/JCI162870"},{"key":"4153_CR17","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1158\/0008-5472.CAN-17-1733","volume":"78","author":"C Liu","year":"2018","unstructured":"Liu, C. et al. Antitumor effects of blocking protein neddylation in T315I-BCR-ABL leukemia cells and leukemia stem cells. Cancer Res. 78, 1522\u20131536. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1733 (2018).","journal-title":"Cancer Res."},{"key":"4153_CR18","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-12-3212","volume":"19","author":"ST Nawrocki","year":"2013","unstructured":"Nawrocki, S. T. et al. Disrupting protein neddylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin. Cancer Res. 19, 3577\u20133590. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3212 (2013).","journal-title":"Clin. Cancer Res."},{"key":"4153_CR19","doi-asserted-by":"publisher","first-page":"112925","DOI":"10.1016\/j.celrep.2023.112925","volume":"42","author":"A Aubry","year":"2023","unstructured":"Aubry, A. et al. Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses. Cell. Rep. 42, 112925. https:\/\/doi.org\/10.1016\/j.celrep.2023.112925 (2023).","journal-title":"Cell. Rep."},{"key":"4153_CR20","doi-asserted-by":"publisher","first-page":"112153","DOI":"10.1016\/j.ejmech.2020.112153","volume":"192","author":"DJ Fu","year":"2020","unstructured":"Fu, D. J. et al. Discovery of novel tertiary amide derivatives as neddylation pathway activators to inhibit the tumor progression in vitro and in vivo. Eur. J. Med. Chem. 192, 112153. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112153 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"4153_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie, A. A. et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543, 733\u2013737. https:\/\/doi.org\/10.1038\/nature21702 (2017).","journal-title":"Nature"},{"key":"4153_CR22","doi-asserted-by":"publisher","unstructured":"Yavuz, A. S., Sozer, N. B. & Sezerman, O. U. Prediction of neddylation sites from protein sequences and sequence-derived properties. BMC Bioinform. 16 Suppl 18 https:\/\/doi.org\/10.1186\/1471-2105-16-S18-S9 (2015).","DOI":"10.1186\/1471-2105-16-S18-S9"},{"key":"4153_CR23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.ade2574","volume":"379","author":"Z Lin","year":"2023","unstructured":"Lin, Z. et al. Evolutionary-scale prediction of atomic-level protein structure with a Language model. Science 379, 1123\u20131130. https:\/\/doi.org\/10.1126\/science.ade2574 (2023).","journal-title":"Science"},{"key":"4153_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with alphafold 3. Nature 630, 493\u2013500. https:\/\/doi.org\/10.1038\/s41586-024-07487-w (2024).","journal-title":"Nature"},{"key":"4153_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/FPC.0b013e328351f3e9","volume":"22","author":"R Benito","year":"2012","unstructured":"Benito, R. et al. Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression. Pharmacogenet Genomics. 22, 381\u2013388. https:\/\/doi.org\/10.1097\/FPC.0b013e328351f3e9 (2012).","journal-title":"Pharmacogenet Genomics"},{"key":"4153_CR26","doi-asserted-by":"publisher","first-page":"117356","DOI":"10.1016\/j.biopha.2024.117356","volume":"179","author":"X Qin","year":"2024","unstructured":"Qin, X., Han, X. & Sun, Y. Discovery of small molecule inhibitors of neddylation catalyzing enzymes for anticancer therapy. Biomed. Pharmacother. 179, 117356. https:\/\/doi.org\/10.1016\/j.biopha.2024.117356 (2024).","journal-title":"Biomed. Pharmacother"},{"key":"4153_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang, Y., Li, S., Wang, Y., Zhao, Y. & Li, Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal. Transduct. Target. Ther. 7, 329. https:\/\/doi.org\/10.1038\/s41392-022-01168-8 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"4153_CR28","doi-asserted-by":"publisher","first-page":"117955491770287","DOI":"10.1177\/1179554917702870","volume":"11","author":"AP Azevedo","year":"2017","unstructured":"Azevedo, A. P. et al. BCR-ABL V280G mutation, potential role in Imatinib resistance: first case report. Clin. Med. Insights Oncol. 11, 1179554917702870. https:\/\/doi.org\/10.1177\/1179554917702870 (2017).","journal-title":"Clin. Med. Insights Oncol."},{"key":"4153_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40364-023-00545-x","volume":"12","author":"D Liu","year":"2024","unstructured":"Liu, D., Che, X. & Wu, G. Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways. Biomark. Res. 12, 5. https:\/\/doi.org\/10.1186\/s40364-023-00545-x (2024).","journal-title":"Biomark. Res."},{"key":"4153_CR30","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.7150\/thno.78876","volume":"13","author":"ZX He","year":"2023","unstructured":"He, Z. X. et al. Targeting Cullin neddylation for cancer and fibrotic diseases. Theranostics 13, 5017\u20135056. https:\/\/doi.org\/10.7150\/thno.78876 (2023).","journal-title":"Theranostics"},{"key":"4153_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13045-023-01485-7","volume":"16","author":"DJ Fu","year":"2023","unstructured":"Fu, D. J. & Wang, T. Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions. J. Hematol. Oncol. 16, 87. https:\/\/doi.org\/10.1186\/s13045-023-01485-7 (2023).","journal-title":"J. Hematol. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04153-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04153-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04153-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:01:45Z","timestamp":1748584905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04153-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4153"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04153-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18978"}}